查詢結果分析
相關文獻
- Combination of Oral Hypoglycemic Agents and Bedtime Insulin with Ultratard HM in Management of Poorly-controlled NIDDM Subjects
- 口服降血糖藥--磺醯尿素類藥物
- Effects of Insulin therapy on Non-Insulin-Dependent Diabetics with Secondary Oral Hypoglycemic Agent Failure
- Troglitazone--新口服降血糖藥物
- 口服降血糖藥
- 糖尿病控制展新迎姿千禧
- 口服降血糖藥物的選擇
- Glimepiride (Amaryl[feb9])--可以隨餐日服一次的口服降血糖藥
- 糖尿病患低血糖之護理
- 合併口服降血糖藥及胰島素治療第二型糖尿病
頁籤選單縮合
題 名 | Combination of Oral Hypoglycemic Agents and Bedtime Insulin with Ultratard HM in Management of Poorly-controlled NIDDM Subjects |
---|---|
作 者 | 莊立民; 戴東原; 林瑞祥; | 書刊名 | 中華民國內分泌暨糖尿病學會會訊 |
卷 期 | 11:4=44 1998.07[民87.07] |
頁 次 | 頁14-20 |
分類號 | 418.271 |
關鍵詞 | 口服降血糖藥; Oral hypoglycemic agents; Long-acting insulin; Type 2 diabetes; Secondary failure; |
語 文 | 英文(English) |
英文摘要 | Low-dose bedtime insulin therapy in combination with oral hypoglycemic agents (OHA) has become an alternative for treatment of NIDDM patients with secondary failure. Pharmacokinetic properties of Ultratard HM insulin with its long action profiles and minimum peak level make it suitable to be used as the basal supplementary insulin without resulting in any complications from hypoglycemia. To evaluate its clinical efficacy, patient compliance, and its possible side effects, 30 NIDDM subjects with secondary failure to OHA were recurited in this study. Ultratard HM insulin was given at an initial dose of 0.15~0.20 U/kg body weight and was adjusted thereafter to achieve better glycemic control. As a whole, low-dose Ultratard HM supplement with OHA improved glycemic control. There was a small increase in body weight at 2~3 months after insulin therapy (p<0.0543). No significant changes in the serum cholesterol and triglyceride levels were found. During treatment period, 2 (6.7%) cases experienced mild hypolycemic symptoms. According to the clinical response, 15 patients (50%) were graded as good responders, 9 patients (3 0%) ere partial responders, and 6 patients (20%) were non-responders. Among the various demographic variables, only waist-hip ratio (WHR) was marginally significantly different between the good and poor responders (p<0.076). The average dose of Ultratard HM used was smaller in the good responders as compared to the poor responders (p < 0.001). Our data confirmed that Ultratard HM bedtime supplement in combination of OHA was effective in the treatment of NIDDM patients with secondary failure to OHA. Overall compliance on combined insulin and OHA was about 80%. Discontinuation of insulin due to symptomatic hypoglycemia was observed in one case (3.3%). Insulin edema was encountered only in one case (3.3%). A lower level of WHR was a strong predictor for good clinical response even at a lower dosage unit used in the NIDDM patients with secondary failure to OHA. |
本系統中英文摘要資訊取自各篇刊載內容。